Track topics on Twitter Track topics that are important to you
Fujirebio Diagnostics, a consolidated subsidiary of Miraca Holdings, has secured approval from the US Food and Drug Administration (FDA) for its Lumipulse G B•R•A•H•M•S procalcitonin (PCT) assay to be tested on Lumipulse G1200 immunoassay platform.
Original Article: FDA approves Fujirebio's Lumipulse G B•R•A•H•M•S PCT assayNEXT ARTICLE
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...
An assay is an analytic procedure for qualitatively assessing or quantitatively measuring the presence or amount or the functional activity of a target entity. This can be a drug or biochemical substance or a cell in an organism or organic sample. ...